Welcome to our dedicated page for Enlivex news (Ticker: ENLV), a resource for investors and traders seeking the latest updates and insights on Enlivex stock.
Enlivex Ltd. develops quality longevity therapeutics and operates a prediction markets treasury alongside its clinical programs. The company’s news centers on Allocetra™, a clinical-stage immunotherapy for inflammatory conditions associated with aging, with a primary focus on moderate-to-severe age-related knee osteoarthritis.
Recurring updates also cover the RAIN token and Rain protocol, including digital asset treasury holdings, exchange listings, decentralized prediction-market infrastructure, tokenized exposure to Enlivex ordinary shares, financial results affected by treasury assets, financing activity, and share repurchase authorization.
Enlivex (NASDAQ: ENLV) announced a $212,000,000 private placement of 212,000,000 ordinary shares at $1.00 per share (an 11.5% premium to the Nov 21, 2025 close), funded in a combination of USD and USDT, with proceeds intended to implement a RAIN prediction‑markets token treasury strategy while continuing core clinical work. The company also announced the appointment of Matteo Renzi, former prime minister of Italy, to the Enlivex board effective November 24, 2025. RAIN is described as a decentralized prediction and options protocol on the Arbitrum network with AI‑resolved markets and a buyback & burn token mechanism.
Enlivex (Nasdaq: ENLV) announced a $212,000,000 PIPE to sell 212,000,000 shares at $1.00 per share (an 11.5% premium to the Nov 21, 2025 close), funded in a combination of USD and USDT.
Proceeds are intended to implement the first RAIN prediction markets token treasury strategy via RAIN token accumulation while the company continues clinical development of Allocetra for knee osteoarthritis. Former Italian prime minister Matteo Renzi will join the board following closing. The closing is expected on or before November 25, 2025, subject to customary conditions. BTIG is sole placement agent.
Enlivex (Nasdaq: ENLV) announced positive six-month topline Phase IIa data for Allocetra in patients with age-related primary moderate-to-severe knee osteoarthritis.
Key findings: durable pain and function improvement versus placebo in the 60+ population (3-month composite: -26.8 vs -13.4, p=0.008; 6-month composite at 61+: -27.8 vs -15.5, p=0.02). The company reported a favorable safety profile through six months and plans a Phase IIb trial to start in H1 2026.
Enlivex Therapeutics (Nasdaq: ENLV) will present Phase IIa 3-month topline data for Allocetra in moderate-to-severe knee osteoarthritis (KOA) at ACR Convergence 2025 on October 28, 2025.
The late-breaking poster reports clinically meaningful and statistically significant pain reduction and function improvement versus placebo in idiopathic age-related KOA patients (≥60 years), who represent >50% of the KOA market and 54% of the study population, and includes new supporting biomarker data.
Poster title: Randomized, Double-Blind, Placebo-Controlled Phase IIa Trial (NCT06233474). Presentation by Prof. Philip Conaghan; Einat Galamidi, MD, CMO, available for meetings.
Enlivex Therapeutics (NASDAQ:ENLV) released a shareholder letter highlighting significant Phase IIa results for Allocetra™ in knee osteoarthritis (KOA) treatment. The trial demonstrated 72% pain reduction versus placebo and 109% function improvement in primary idiopathic age-related osteoarthritis patients aged 60 and above.
The treatment showed particularly strong results in older patients, with efficacy exceeding FDA thresholds for Phase III trials. Allocetra™ was well-tolerated with no drug-related serious adverse events. The company plans to release six-month data in November 2025 and initiate a Phase IIb trial in Q2 2026, focusing on primary KOA patients.
The potential market is significant, with over 32 million Americans affected by KOA, projected to reach 78 million by 2040. Enlivex is pursuing partnership opportunities with larger companies and non-dilutive funding options.
Enlivex Therapeutics (NASDAQ:ENLV) has secured an Israeli patent (No. 290470) for using Allocetra™ to treat osteoarthritis patients, extending protection through 2040. The company recently reported promising Phase IIa results showing significant improvements in knee osteoarthritis patients, including:
- 24% reduction in knee pain and 26% improvement in knee function in the overall modified intention-to-treat population
- 72% reduction in knee pain and 109% improvement in knee function in age-related primary osteoarthritis patients versus placebo
These results demonstrate clinically meaningful and statistically significant effects in common Phase III primary endpoints for knee osteoarthritis trials.
Enlivex Therapeutics (NASDAQ:ENLV) announced positive three-month topline data from its Phase I/II trial of Allocetra™ for moderate-to-severe knee osteoarthritis. The trial demonstrated significant improvements across all efficacy endpoints, with the treatment arm showing a 24% reduction in knee pain and 26% improvement in knee function versus placebo.
Notably, in age-related primary osteoarthritis patients, the results were even more impressive, showing a 72% reduction in knee pain and 95% improvement in knee function compared to placebo - achieving statistically significant effects in common Phase III primary endpoints. The treatment demonstrated a favorable safety profile with no severe adverse events, showing only mild to moderate, transient, and treatable side effects.
Enlivex Therapeutics (Nasdaq: ENLV) announced a webinar scheduled for August 18, 2025, at 8:00 AM ET to present 3-month topline results from its Phase IIa trial of Allocetra™ for moderate to severe knee osteoarthritis. The study, ENX-CL-05-001, is a double-blind, randomized, placebo-controlled multi-center trial.
The trial has enrolled 134 patients who have completed the 3-month follow-up period. The Phase IIa stage follows a completed Phase I open-label dose-escalation study that evaluated safety, tolerability, and optimal dosing. The trial addresses knee osteoarthritis, which affects over 32.5 million Americans and 300 million people worldwide, with 40% of men and 47% of women developing it in their lifetimes.
Enlivex Therapeutics (NASDAQ:ENLV) has confirmed the target date of August 18, 2025 for announcing topline data from its Phase II trial of Allocetra™ in patients with moderate to severe knee osteoarthritis. The trial has completed the three-month follow-up period for all 134 patients, marking a significant milestone in the study.
The Phase I/II trial consists of two stages: a Phase I safety run-in, open-label dose escalation phase, followed by a Phase IIa double-blind, randomized, placebo-controlled multi-centered trial. The study's key endpoints include safety assessment and measurement of changes in knee pain and function at three, six, and twelve months post-treatment.